The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M09 | Other drugs for disorders of the musculo-skeletal system | |
3
|
M09A | Other drugs for disorders of the musculo-skeletal system | |
4
|
M09AX | Other drugs for disorders of the musculo-skeletal system | |
5
|
M09AX14 |
| Active Ingredient |
|---|
|
Givinostat is a class I and II histone deacetylase (HDAC) inhibitor that modulates the uncontrolled HDAC activity in dystrophic muscles, which contributes to the pathology of Duchenne muscular dystrophy (DMD). Givinostat HDAC inhibition has been shown to reduce muscle fiber damage, chronic muscular inflammation, fibrosis, fat deposition, and to promote mitochondrial biogenesis. |
| Document | Type | Information Source | |
|---|---|---|---|
| DUVYZAT Oral suspension | MPI, EU: SmPC | European Medicines Agency (EU) | |
| DUVYZAT Oral suspension | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.